CY1115376T1 - Βελτιωμενη μεθοδος - Google Patents
Βελτιωμενη μεθοδοςInfo
- Publication number
- CY1115376T1 CY1115376T1 CY20141100562T CY141100562T CY1115376T1 CY 1115376 T1 CY1115376 T1 CY 1115376T1 CY 20141100562 T CY20141100562 T CY 20141100562T CY 141100562 T CY141100562 T CY 141100562T CY 1115376 T1 CY1115376 T1 CY 1115376T1
- Authority
- CY
- Cyprus
- Prior art keywords
- lenalidomide
- crystalline
- isoindol
- dione
- piperidine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 abstract 4
- 229960004942 lenalidomide Drugs 0.000 abstract 3
- JKPJLYIGKKDZDT-UHFFFAOYSA-N 3-(7-nitro-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C=2C([N+](=O)[O-])=CC=CC=2C(=O)N1C1CCC(=O)NC1=O JKPJLYIGKKDZDT-UHFFFAOYSA-N 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Optical Communication System (AREA)
- Lighting Device Outwards From Vehicle And Optical Signal (AREA)
- Glass Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN383KO2009 | 2009-03-02 | ||
| IN463KO2009 | 2009-03-16 | ||
| EP10707950.1A EP2403845B1 (en) | 2009-03-02 | 2010-03-01 | Improved process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115376T1 true CY1115376T1 (el) | 2017-01-04 |
Family
ID=54290149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100562T CY1115376T1 (el) | 2009-03-02 | 2014-07-24 | Βελτιωμενη μεθοδος |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8946265B2 (https=) |
| EP (1) | EP2403845B1 (https=) |
| JP (1) | JP5727944B2 (https=) |
| CN (1) | CN102414196A (https=) |
| AU (1) | AU2010220204B2 (https=) |
| CA (1) | CA2753241C (https=) |
| CY (1) | CY1115376T1 (https=) |
| DK (1) | DK2403845T3 (https=) |
| ES (1) | ES2487215T3 (https=) |
| HR (1) | HRP20140686T1 (https=) |
| NZ (1) | NZ595492A (https=) |
| PL (1) | PL2403845T3 (https=) |
| PT (1) | PT2403845E (https=) |
| SI (1) | SI2403845T1 (https=) |
| SM (1) | SMT201400100B (https=) |
| WO (1) | WO2010100476A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| TWI475014B (zh) * | 2009-09-17 | 2015-03-01 | Scinopharm Taiwan Ltd | 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法 |
| WO2011064574A1 (en) | 2009-11-24 | 2011-06-03 | Generics [Uk] Limited | Hplc method for detecting lenalidomide |
| WO2011111053A1 (en) * | 2010-03-08 | 2011-09-15 | Natco Pharma Limited | Anhydrous lenalidomide form-i |
| KR20130050952A (ko) | 2010-06-16 | 2013-05-16 | 브루스 챈들러 메이 | 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도 |
| WO2013005229A1 (en) * | 2011-07-05 | 2013-01-10 | Hetero Research Foundation | Process for lenalidomide |
| US9540341B2 (en) | 2011-07-19 | 2017-01-10 | Amplio Pharma, Llc | Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CN102838586A (zh) * | 2012-09-20 | 2012-12-26 | 重庆泰濠制药有限公司 | 一种制备来那度胺的方法 |
| WO2014164285A2 (en) | 2013-03-13 | 2014-10-09 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of vasculitis |
| RU2015134423A (ru) | 2013-03-13 | 2017-04-26 | Инфламматори Респонс Ресёрч, Инк. | Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств |
| MX382776B (es) | 2013-03-13 | 2025-03-13 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. |
| US9808450B2 (en) | 2013-03-26 | 2017-11-07 | Celgene Corporation | Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof |
| CN103601717A (zh) * | 2013-10-09 | 2014-02-26 | 湖南华腾制药有限公司 | 一种来那度胺的新型制备方法 |
| LV14985B (lv) | 2013-10-14 | 2015-06-20 | Latvijas Organiskās Sintēzes Institūts | Lenalidomīda iegūšanas process |
| WO2014155371A2 (en) * | 2014-04-26 | 2014-10-02 | Shilpa Medicare Limited | Crystalline lenalidomide process |
| WO2016024286A2 (en) * | 2014-08-11 | 2016-02-18 | Avra Laboratories Pvt. Ltd. | An improved process for synthesis of lenalidomide |
| EP3183244B1 (en) * | 2014-08-19 | 2019-04-10 | Synthon BV | Process for making crystalline form a of lenalidomide |
| WO2016044095A1 (en) | 2014-09-15 | 2016-03-24 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| WO2017109041A1 (en) * | 2015-12-22 | 2017-06-29 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant |
| US10899793B2 (en) | 2016-05-27 | 2021-01-26 | Regents Of The University Of Minnesota | Melanocortin ligands and methods of use thereof |
| US11124541B2 (en) | 2016-10-18 | 2021-09-21 | Regents Of The University Of Minnesota | Chimeric melanocortin ligands and methods of use thereof |
| EP3687987A4 (en) * | 2017-09-27 | 2021-03-24 | Biocon Limited | CRYSTALLINE FORMS OF LENALIDOMIDE |
| US11452722B2 (en) | 2018-01-11 | 2022-09-27 | Natco Pharma Limited | Stable pharmaceutical compositions comprising lenalidomide |
| US11332499B2 (en) | 2018-08-16 | 2022-05-17 | Regents Of The University Of Minnesota | Cyclic peptides and methods of use thereof |
| CN111196800B (zh) * | 2018-11-19 | 2022-10-11 | 欣凯医药化工中间体（上海）有限公司 | 一种制备来那度胺的方法 |
| WO2021236518A1 (en) | 2020-05-19 | 2021-11-25 | IRR, Inc. | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof |
| WO2022144924A1 (en) * | 2021-01-04 | 2022-07-07 | Avra Laboratories Pvt. Ltd. | An improved process for synthesis of lenalidomide |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| BRPI0514865A (pt) * | 2004-09-03 | 2008-06-24 | Celgene Corp | processo para preparar um composto |
| US8304250B2 (en) | 2007-04-16 | 2012-11-06 | Momenta Pharmaceuticals, Inc. | Multi-dimensional chromatographic methods for separating N-glycans |
| CA2709262A1 (en) | 2007-12-14 | 2009-06-25 | Generics [Uk] Limited | New hplc method |
| CA2717326C (en) | 2008-03-11 | 2018-10-23 | Dr. Reddy's Laboratories Ltd. | Preparation of lenalidomide |
| WO2010061209A1 (en) | 2008-11-03 | 2010-06-03 | Generics [Uk] Limited | A crystalline form of lenalidomide and a process for its preparation |
| WO2011064574A1 (en) | 2009-11-24 | 2011-06-03 | Generics [Uk] Limited | Hplc method for detecting lenalidomide |
-
2010
- 2010-03-01 CN CN2010800195527A patent/CN102414196A/zh active Pending
- 2010-03-01 PT PT107079501T patent/PT2403845E/pt unknown
- 2010-03-01 NZ NZ595492A patent/NZ595492A/xx not_active IP Right Cessation
- 2010-03-01 CA CA2753241A patent/CA2753241C/en active Active
- 2010-03-01 HR HRP20140686AT patent/HRP20140686T1/hr unknown
- 2010-03-01 EP EP10707950.1A patent/EP2403845B1/en active Active
- 2010-03-01 WO PCT/GB2010/050352 patent/WO2010100476A2/en not_active Ceased
- 2010-03-01 JP JP2011552515A patent/JP5727944B2/ja not_active Expired - Fee Related
- 2010-03-01 SI SI201030679T patent/SI2403845T1/sl unknown
- 2010-03-01 US US13/254,249 patent/US8946265B2/en active Active
- 2010-03-01 DK DK10707950.1T patent/DK2403845T3/da active
- 2010-03-01 AU AU2010220204A patent/AU2010220204B2/en not_active Ceased
- 2010-03-01 ES ES10707950.1T patent/ES2487215T3/es active Active
- 2010-03-01 PL PL10707950T patent/PL2403845T3/pl unknown
-
2014
- 2014-07-24 CY CY20141100562T patent/CY1115376T1/el unknown
- 2014-07-28 SM SM201400100T patent/SMT201400100B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2753241C (en) | 2015-06-16 |
| AU2010220204B2 (en) | 2015-10-08 |
| SI2403845T1 (sl) | 2014-09-30 |
| DK2403845T3 (da) | 2014-08-04 |
| PL2403845T3 (pl) | 2014-09-30 |
| US8946265B2 (en) | 2015-02-03 |
| ES2487215T3 (es) | 2014-08-20 |
| WO2010100476A2 (en) | 2010-09-10 |
| PT2403845E (pt) | 2014-08-04 |
| SMT201400100B (it) | 2014-11-10 |
| NZ595492A (en) | 2013-07-26 |
| JP5727944B2 (ja) | 2015-06-03 |
| US20120071509A1 (en) | 2012-03-22 |
| JP2012519207A (ja) | 2012-08-23 |
| EP2403845A2 (en) | 2012-01-11 |
| HRP20140686T1 (hr) | 2014-09-26 |
| CN102414196A (zh) | 2012-04-11 |
| WO2010100476A3 (en) | 2011-06-16 |
| AU2010220204A1 (en) | 2011-10-20 |
| EP2403845B1 (en) | 2014-04-30 |
| CA2753241A1 (en) | 2010-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115376T1 (el) | Βελτιωμενη μεθοδος | |
| EA201391318A1 (ru) | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение | |
| CY1119474T1 (el) | Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης | |
| CY1117331T1 (el) | Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων | |
| ATE486601T1 (de) | Verwendung von 3- (4-amino-1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen | |
| EA201001126A1 (ru) | Пирролопиримидины и пирролопиридины | |
| EA201171151A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
| CY1118416T1 (el) | Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα | |
| GEP20135863B (en) | Substituted piperidines as ccr3 antagonists | |
| EA201390934A1 (ru) | Композиции и способы модулирования fxr | |
| CY1118630T1 (el) | Στερεες μορφες 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλο)-κυκλοπροπανοκαρβοξαμ1δο)-3-μεθυλοπυριδιν-3-υλο)-βενζοϊκου οξεος | |
| EA201200741A1 (ru) | Способ получения этексилата дабигатрана | |
| EA201071291A2 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
| UA112281C2 (uk) | Стабільні інсектицидні композиції і способи їх отримання | |
| CY1111927T1 (el) | Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων | |
| EA201070148A1 (ru) | Соединения и способы модулирования фарнезоидного рецептора x (fxr) | |
| EA201590330A1 (ru) | Соли и твердые формы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и включающие их композиции и способы их применения | |
| MX385217B (es) | Antagonistas de actriib y dosificación y usos de los mismos. | |
| NO20076635L (no) | Krystallinske og andre former for 4-amino-5-fluor-3-[6-(4-metylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-kinolin-2-on-melkesyresalter | |
| EA201391797A1 (ru) | 3-спироциклические пиперидиновые производные в качестве агонистов грелиновых рецепторов | |
| EA201100161A1 (ru) | Производные хинуклидина карбоната и их медицинские композиции | |
| EA201100517A1 (ru) | Способ получения дабигатрана и его промежуточные соединения | |
| EA201190017A1 (ru) | Аминоэфирные производные алкалоидов и их медицинские композиции | |
| WO2013012485A3 (en) | Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | |
| EA201270302A1 (ru) | Безводные формы производных пиридина |